Scynexis Inc. (SCYX), which is in exclusive license deal with GSK plc (GSK, GSK.L) for antifungal drug Brexafemme (ibrexafungerp tablets), said it is recalling the drug from the market and placing a temporary hold on clinical studies of ibrexafungerp, citing cross contamination concerns.
from RTT - Before the Bell https://ift.tt/CMjP8sK
via IFTTT
No comments:
Post a Comment